10-K: BriaCell Therapeutics Corp. Reports Full Year 2024 Results, Highlights Clinical Progress

BriaCell Therapeutics Corp. released its annual report for the fiscal year ended July 31, 2024, detailing financial results and clinical advancements in its immunotherapy programs.

Summary

• BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has released its annual report for the fiscal year ended July 31, 2024.
• The company is focused on developing novel immunotherapies for cancer treatment, with its lead candidate, Bria-IMT, in a pivotal Phase 3 study for metastatic breast cancer.
• BriaCell reported a net loss of $4,791,466 for the fiscal year 2024, compared to a net loss of $20,302,394 in 2023.
• Research and development expenses increased to $27,177,807 in 2024 from $15,336,638 in 2023, primarily due to the expansion of the Bria-IMT trial and higher clinical trial costs.
• The company's cash and cash equivalents decreased by $20,389,003 during the year, ending at $862,089.
• BriaCell is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, and a soluble CD80 protein therapeutic.
• The company has a 51.2% interest in BC Therapeutics, which is accounted for using the equity method.
• BriaCell completed a spin-out transaction, creating BriaPro Therapeutics Corp. as a 2/3rd owned subsidiary.
• The company has a significant number of outstanding options and warrants, which could dilute existing shareholders.
• BriaCell is subject to various risks, including the need for additional capital, reliance on third parties, and regulatory approvals.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical results and progress in development, the financial situation and going concern risks temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• BriaCell's Bria-IMT shows promising clinical results with a median overall survival of 13.4 months in Phase 2 trials, exceeding benchmarks.
• The company has received Fast Track Designation from the FDA for Bria-IMT, potentially accelerating the approval process.
• BriaCell is expanding its pipeline with personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, and a soluble CD80 protein therapeutic.
• The company has secured manufacturing agreements with UC Davis and Fuji for Bria-IMT production.
• BriaCell has a partnership with New York Cancer & Blood Specialists for its pivotal Phase 3 study.
• The company has received positive feedback from the FDA for Bria-PROS+ for prostate cancer, waiving the animal toxicology and pharmacokinetic studies requirement.
• BriaCell has reported a 100% resolution of brain metastasis in a breast cancer patient with an eye-bulging tumor.
• The company has successfully raised additional capital through registered direct offerings in September and October 2024.

Negatives

• BriaCell reported a net loss of $4,791,466 for the fiscal year 2024, although this is an improvement from the $20,302,394 loss in 2023.
• The company's cash and cash equivalents decreased significantly, ending at $862,089.
• BriaCell is heavily reliant on third-party contract manufacturers and clinical research organizations.
• The company has a significant number of outstanding options and warrants, which could dilute existing shareholders.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is a pre-revenue clinical stage company with an unproven market for its product candidates.

Risks

• The company has a history of losses and may not achieve profitability.
• There is substantial doubt about the company's ability to continue as a going concern.
• BriaCell is a pre-revenue clinical stage company and is developing novel technologies that may not be effective or safe.
• The company has an unproven market for its product candidates.
• BriaCell is heavily reliant on third-parties to carry out a large portion of its business.
• Pre-clinical studies and initial clinical trials are not necessarily predictive of future results.
• The company must obtain additional capital to continue its operations.
• BriaCell is highly dependent on its key personnel.
• The company may not succeed in completing the development of its products, commercializing its products or generating significant revenues.
• BriaCell may not successfully develop, maintain and protect its proprietary products and technologies.
• Changes in legislation and regulations may affect the company's revenue and profitability.
• If the company or its licensees are unable to obtain regulatory approval, they will be unable to commercialize their therapeutic candidates.
• Short sellers may be manipulative and may drive down the market price of the company's common shares.
• The company's 2/3rd owned subsidiary BriaPro Therapeutics Corp. may not generate revenue as expected.
• Clinical trials involve a lengthy and expensive process with uncertain outcomes.
• Future issuance of the company's common shares could dilute the interests of existing shareholders.
• The company has a significant number of options and warrants outstanding, which may make it more difficult to raise additional equity capital.
• The company is subject to cybersecurity risks and data breaches.
• The company may be subject to product liability lawsuits.
• Global economic uncertainty and financial market volatility could make it more difficult for the company to access financing.
• The company may be adversely affected by the effects of inflation.

Future Outlook

The company anticipates that additional capital will be required to complete its current research and development programs. It is anticipated that future research, additional pre-clinical and toxicology studies and manufacturing initiatives, including to prepare for market approval and successful product market launch, will require additional funds.

Management Comments

• Management expects to continue to incur substantial operating losses unless and until such time as product sales generate sufficient revenues to fund continuing operations.
• Management believes that it can be successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so.

Industry Context

The document highlights the competitive landscape in cancer immunotherapy, noting the presence of large pharmaceutical companies and smaller niche players. It also emphasizes the high unmet medical need in late-stage breast cancer, which could facilitate accelerated approval of Bria-IMT.

Comparison to Industry Standards

• The document compares BriaCell's Bria-IMT median overall survival of 13.4 months to published studies showing 6.7-9.8 months for similar patients, indicating a potential improvement.
• The document also compares BriaCell's progression-free survival (PFS) of 4.1 months in ADC resistant patients to other studies showing PFS of 1.7 to 2.3 months.
• The document notes that the clinical benefit rate of 55% in BriaCell's Phase 2 study is much higher than comparable studies.
• The document references several studies including Cortes J, et al. Annals of Oncology 2018, Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17, OShaughnessy J et al. Breast Cancer Res Treat. 2022, and Tripathy D, et al. JAMA Oncol. 2022 to benchmark BriaCell's results against other treatments for metastatic breast cancer.

Related Party Transactions

• On May 17, 2024, the company issued and sold to a director 902,935 common shares together with warrants to purchase up to 902,935 common shares at a combined purchase price of $2.215 per share and accompanying warrant.

Stakeholder Impact

• Shareholders face the risk of dilution from future share issuances and the potential for loss of investment due to the company's financial challenges.
• Employees may be affected by the company's financial instability and potential restructuring.
• Patients may benefit from the development of new cancer treatments, but the success of these treatments is not guaranteed.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to advance its Bria-IMT targeted immunotherapy in the pivotal Phase 3 study.
• BriaCell will continue to develop its personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+.
• The company will continue to optimize the structure of its proprietary protein kinase C delta inhibitors and advance to the candidates election stage.
• Human clinical studies for BriaPro are expected to be initiated in the first half of 2025.
• Human clinical studies for BriaPro's protein kinase C delta inhibitors are expected to be initiated in the second half of 2025.
• The company will continue to recruit additional sites to speed up the patient recruitment process for the Phase 3 study.

Key Dates

Keywords

immunotherapy, breast cancer, metastatic breast cancer, Bria-IMT, Bria-OTS, clinical trials, biotechnology, cancer treatment, FDA, immunooncology, warrants, options, share offering, capital raise, going concern